Purpose: To compare a technology-based supportive cancer care approach with a team-based supportive cancer care approach.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV breast cancer that is newly diagnosed or whose cancer has come back. View full eligibility criteria

Purpose: To determine if observation will result in the same risk of cancer coming back (recurrence) as pembrolizumab (Keytruda®) immunotherapy after neoadjuvant (before surgery) therapy and surgery.

Who is this for?: People with stage I, stage II, or stage III triple negative (ER- or ER low, PR- or PR low, HER2-) breast cancer who have no residual disease after neoadjuvant (before surgery) chemotherapy and pembolizumab (Keytruda®) and negative margins after surgery. You must have received surgery less than 3 months ago. View full eligibility criteria

Purpose: To study a virtual patient navigation program to support people with breast cancer.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have not yet started treatment or are currently receiving treatment. You must speak English, Mandarin/Cantonese/Chinese, or Spanish. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of standard of care therapy compared to standard of care therapy with an experimental drug chosen based on your tumor's biomarkers.

Who is this for?: People with stage II or stage III breast cancer who have not yet received treatment and whose cancer is high-risk for recurrence. View full eligibility criteria

Purpose: To learn if risk-based breast screening is as safe and effective as annual mammogram screening for reducing risk and detecting breast cancer.

Who is this for?: Women between the ages of 40 and 70 who have never been diagnosed with breast cancer or ductal carcinoma in situ (DCIS). View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of using a tumor's genetic profile to select an FDA-approved targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with no standard treatment options. You must have results from a genomic or immunohistochemistry test approved by TAPUR. View full eligibility criteria

Purpose: To create a large registry of tumor samples to help researchers find new cancer biomarkers and design future clinical trials.

Who is this for?: People with stage I, stage II, or stage III breast cancer who received MammaPrint testing, with or without BluePrint genomic testing, of their tumor. View full eligibility criteria

Purpose: To look at the safety and effects (good and bad) of combining the immunotherapy drug avelumab (Bavencio®) with binimetinib, utomilumab, or PF-04518600.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR- and HER2-) or ER Low (1%-10% ER) breast cancer who have not had more than three lines of chemotherapy and not more than one checkpoint inhibitor. View full eligibility criteria

Purpose: To collect tumor samples that will be used to develop OncoPrism™, a test that helps providers predict response to immunotherapy.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) triple negative (ER-, PR-, HER2-) breast cancer who have received or are planning to receive treatment with a PD-1/PD-L1 inhibitor. You must have received a biopsy before beginning treatment with a PD-1/PD-L1 inhibitor. View full eligibility criteria

Purpose: To study the safety, side effects, dose, and anti-cancer activity of giving PF-07248144 alone, in combination with fulvestrant, or with palbociclib and letrozole.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen-receptor positive (ER+), HER2-negative (HER2-) breast cancer whose disease progressed after receiving a CDK 4/6 inhibitor and anti-estrogen therapy. View full eligibility criteria

Purpose: To study the anti-cancer activity and safety of giving the experimental anti-estrogen therapy giredestrant alone or with a CDK 4/6 inhibitor, an AKT inhibitor, a PI3K inhibitor, or chemotherapy.

Who is this for?: Women with advanced (some stage III) or metastatic (stage IV) estrogen-receptor positive (ER+), HER2-negative (HER2-) breast cancer whose disease progressed while taking anti-hormone therapy with a CDK 4/6 inhibitor and who have not received chemotherapy for metastatic disease. View full eligibility criteria

Purpose: To study the effects (good and bad) and anti-cancer activity of hormone therapy alone or with radiation after a lumpectomy.

Who is this for?: People with stage I hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received a lumpectomy within the past 3 months. You must not have received chemotherapy or radiation. View full eligibility criteria

Purpose: To study the dose, safety, side effects, and anti-cancer activity of giving the targeted therapies capivasertib and palbociclib (Ibrance®) with the anti-estrogen therapy fulvestrant (Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer. Your cancer must have progressed on anti-estrogen therapy. View full eligibility criteria

Purpose: To study and compare the safety, side effects, and anti-cancer activity of giving Herceptin Hylecta (trastuzumab by injection) with chemotherapy to giving it with an antibody-drug conjugate.

Who is this for?: People with stage I HER2-positive (HER2+) breast cancer who have already had surgery and completed radiation therapy. View full eligibility criteria

Purpose: To study the safety, best dose, and effects (good and bad) of 177Lu-FAP-2286, an experimental radioactive drug.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have received at least 2 lines of therapy for advanced disease. View full eligibility criteria

Purpose: To study the effects (good and bad) of antibiotics after mastectomy with immediate reconstruction on infection and the microbiome.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, or some stage III breast cancer or people at risk of breast cancer who are planning to receive a mastectomy with immediate reconstruction. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of NX-1607, an experimental CBL-B inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer with no standard treatment options available. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of GLSI-100, an experimental immunotherapy.

Who is this for?: People with stage I, stage II, or stage III HER2 positive (HER2+) breast cancer who have completed standard treatment. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of XMT-1660, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of AZD9574, an experimental PARP inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer with a tumor or inherited BRCA1, BRCA2, PALB2, RAD51C, or RAD51D mutation. You must not have received treatment with a PARP inhibitor. You must have at least 1 tumor that has not been treated with radiation. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of OP-1250, an experimental hormone therapy, with ribociclib (Kisqali®) CDK 4/6 inhibitor or alpelisib (Piqray®) PI3K inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received 1-2 hormone therapies for advanced or metastatic disease. You must not have received more than 1 chemotherapy for advanced or metastatic disease. View full eligibility criteria

Purpose: To use genetic testing to match people to treatments and help doctors plan better treatments.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have received at least 1 line of therapy for advanced disease or who have no standard treatment options available. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of sacituzumab govitecan (Trodelvy®) antibody drug conjugate with pembrolizumab (Keytruda®) immunotherapy, a PD-1 inhibitor.

Who is this for?: People with stage I, stage II, or stage III triple negative (ER-, PR-, HER2-) breast cancer with residual disease after neoadjuvant (before surgery) treatment and surgery. You must not have a BRCA mutation. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of niraparib PARP inhibitor with irinotecan chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with a BRCA1, BRCA2, ATM, and/or PALB2 mutation. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of standard of care anti-HER2 targeted therapy with and without adjuvant (after surgery) radiation.

Who is this for?: People at least 40 years old with stage 0 (DCIS), stage I, stage II, or some stage III HER2 positive (HER2+) breast cancer who have received a lumpectomy, chemotherapy, and anti-HER2 targeted therapy. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of STX-478, an experimental PI3K inhibitor, alone or with fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with advanced (stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with a PI3K mutation. You must not have a PTEN, AKT, or mTOR mutation. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of adding chemotherapy to treatment with aromatase inhibitor and ovarian function suppression.

Who is this for?: Premenopausal women 18-60 years old with stage I, stage II, or some stage III hormone receptor positive or low (ER+ or ER low and/or PR+ or PR low), HER2 negative (HER2-) breast cancer who have received surgery and have an Oncotype DX score of less than 26. View full eligibility criteria

Purpose: To study how well computer games improve thinking problems.

Who is this for?: People with stage I, stage II, or stage III breast cancer who have completed treatment 6 months to 5 years ago. You must be experiencing problems thinking. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of shorter chemotherapy and immunotherapy treatment without doxorubicin (Adriamycin®) chemotherapy before surgery (neoadjuvant).

Who is this for?: People with stage I, stage II, or some stage III triple negative (ER- or ER low, PR- or PR low, HER2-) breast cancer who have not yet received treatment. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of standard of care neoadjuvant (before surgery) chemotherapy with and without durvalumab (Imfinzi®) PD-L1 inhibitor.

Who is this for?: Women with newly diagnosed stage II or stage III hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) or HER2 low breast cancer who have not yet received treatment. You must have a MammaPrint score of -1.0 to -0.57. View full eligibility criteria

Purpose: To study if hormone therapy and active monitoring (MRIs and mammograms) is an effective way to treat and manage DCIS.

Who is this for?: Women with stage 0 (DCIS) hormone receptor positive (ER+ and/or PR+) breast cancer who have not yet received surgery. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of enzalutamide (Xtandi®), an experimental hormone therapy, alone or with mifepristone, an experimental hormone therapy, compared to standard of care chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER- or ER low, PR- or PR low, HER2-) or ER low, androgen receptor positive (AR+) breast cancer who have received 0-1 lines of chemotherapy for advanced disease. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of disitamab vedotin, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 low or HER2 positive (HER2+) breast cancer who have received trastuzumab deruxtecan (Enhertu®) or sacituzumab govitecan (Trodelvy®). View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ASTX727, an experimental targeted therapy, with olaparib (Lynparza®) PARP inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with BRCA1, BRCA2, PALB2, ATM, and/or CHEK2 inherited or tumor mutations who have no standard treatment options available. View full eligibility criteria

Purpose: To study the ability of the AMMA Portable Scalp Cooling System to reduce hair loss in people receiving chemotherapy.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are planning to receive paclitaxel (Taxol®) or docetaxel (Taxotere®) chemotherapy. View full eligibility criteria

Purpose: To study the safety, best dose, and effects (good and bad) of alisertib, an experimental AURKA inhibitor, with standard of care hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received at least two hormone therapies including a CDK4/6 inhibitor with hormone therapy for advanced disease. You must not have received chemotherapy for advanced disease. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of adjuvant (after surgery) sacituzumab tirumotecan, an experimental antibody drug conjugate (ADC), with pembrolizumab (Keytruda®) PD-1 inhibitor compared to standard of care pembrolizumab (Keytruda®) with or without chemotherapy.

Who is this for?: People with stage I, stage II, and stage III triple negative (ER-, PR-, HER2-) breast cancer who received neoadjuvant (before surgery) pembrolizumab (Keytruda®) with chemotherapy and surgery. You must have cancer cells remaining (non-pathologic complete response) after surgery less than 3 months ago. View full eligibility criteria

Purpose: To study the potential benefits and harms of cannabis products for cancer-related symptoms.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive or are receiving (within 2 months) treatment with chemotherapy, targeted therapy, and/or an immune checkpoint inhibitor (pembrolizumab (Keytruda®) or dostarlimab (Jemperli®)). You must be using cannabis products. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of zanidatamab, an experimental anti-HER2 targeted therapy, with chemotherapy compared to trastuzumab (Herceptin®) anti-HER2 targeted therapy with chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have received trastuzumab deruxtecan (Enhertu®, T-DXd). View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of elacestrant hormone therapy compared to standard of care hormone therapy.

Who is this for?: People with stage I, stage II, or some stage III estrogen receptor positive (ER+), HER2 negative (HER2- or HER2 low), node positive breast cancer who have received surgery and have a high risk of recurrence. You must be currently receiving hormone therapy for at least 2 years but no more than 5 years. View full eligibility criteria

Purpose: To test the safety and effectiveness of the sequence of 2 types of antibody drug conjugates (ADCs) to learn whether the treatment works for people with metastatic HER2 low breast cancer.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 low breast cancer. You must not have received more than 2 lines of chemotherapy or antibody drug conjugates for advanced disease. View full eligibility criteria

Purpose: To study the safety, best dose, and effects (good and bad) of MOMA-313, an experimental DNA polymerase theta inhibitor, alone or with olaparib (Lynparza®) PARP inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with a BRCA1, BRCA2, PALB2, ATM, or CHEK2 mutation. View full eligibility criteria

Purpose: To study the safety, best dose, and effects (good and bad) of BBO-10203, an experimental targeted therapy, with trastuzumab (Herceptin®) anti-HER2 targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have received at least 2 lines of anti-HER2 targeted therapy or hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have no standard treatment options available. View full eligibility criteria

Purpose: To study if the Ayurveda nutrition, yoga, and healing touch program improves quality of life and cancer-associated symptoms.

Who is this for?: People with stage I, stage II, or stage III breast cancer who completed treatment less than 3 years ago. You must have received chemotherapy. View full eligibility criteria

Purpose: To study the safety, best dose, and effects (good and bad) of MEN2312, an experimental KAT6 inhibitor, alone or with elacestrant (Orserdu®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+) breast cancer who have received a CDK4/6 inhibitor with hormone therapy for advanced disease. You must have received no more than 6 lines of therapy for advanced disease, including no more than 2 lines of chemotherapy and/or antibody drug conjugates (ADC). View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of PF-07220060, an experimental CDK4 inhibitor, with letrozole (Femara®) hormone therapy compared to standard of care treatment.

Who is this for?: People with newly diagnosed advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have not yet received treatment for advanced disease. View full eligibility criteria

Purpose: To study the safety, best dose, and effects (good and bad) of CLSP-1025, an experimental immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HLA-A*02:01 positive breast cancer with p53 R175H mutations who have no standard treatment options available. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of sacituzumab tirumotecan, an experimental antibody drug conjugate (ADC), alone or with pembrolizumab (Keytruda®) immunotherapy compared to standard of care chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have not yet received treatment for advanced disease. Your cancer must express PD-L1 at a combined positive score (CPS) of less than 10. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of receiving HER2 targeted therapy for 6 months vs 1 year.

Who is this for?: People with stage I, stage II, or some stage III HER2 positive (HER2+) breast cancer who had a complete response (no cancer is left) after receiving chemotherapy with trastuzumab (Herceptin®) before surgery (neoadjuvant). You must have received surgery and received or plan to receive radiation. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of RLY-2608 PI3Kα inhibitor plus fulvestrant (Faslodex®) hormone therapy versus capivasertib (Truqap®) AKT inhibitor plus fulvestrant (Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with a PIK3CA mutation whose cancer has progressed while receiving 1 or 2 lines of hormone therapy and a CDK4/6 inhibitor. You must not have received certain treatments that are listed below. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ETX-636, an experimental targeted therapy, with fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with PIK3CA mutations who have received at least 1 CDK4/6 inhibitor and hormone therapy. View full eligibility criteria

Purpose: To study cancer detection with a screening MRI scan.

Who is this for?: Women with a negative or benign mammogram who are considered high-risk by Mirai. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ORIC-114, an experimental x, alone or with chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have no standard treatment options available. View full eligibility criteria

Purpose: To compare the effects (good and bad) of radiation therapy to no radiation therapy in patients with low-risk breast cancer who have had surgery.

Who is this for?: Women with stage I, stage II, or some stage III breast cancer who has been treated with breast cancer surgery and has an Oncotype DX recurrence score less than 18. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of inavolisib (Itovebi®) PI3K inhibitor with palbociclib (Ibrance®) CDK4/6 inhibitor and letrozole (Femara®) aromatase inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with a PIK3CA mutation. You must have been diagnosed with de novo advanced/metastatic breast cancer or received at least 2 years of hormone therapy and completed hormone therapy at least 1 year before your advanced/metastatic diagnosis. You must have not yet received treatment for advanced disease. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of giredestrant, an experimental hormone therapy, compared with fulvestrant (Faslodex®) hormone therapy in combination with a CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who not have received treatment (except for surgery or radiation) for advanced disease. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of BMS-986500, a CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+) breast cancer. View full eligibility criteria

Purpose: To compare the safety, effects (good and bad), and anti-cancer activity of Tersolisib (LY4064809), an experimental PI3Ka inhibitor, with standard of care CDK4/6 inhibitor and hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) or HER2 low breast cancer with a PIK3CA mutation. You may have received 0-2 prior treatments for advanced or metastatic breast cancer. View full eligibility criteria

Purpose: To study the ability of Guardant Reveal, a new blood test, to detect residual disease and recurrence after treatment.

Who is this for?: People with stage I, stage II, or stage III breast cancer who have residual disease (leftover cancer cells in your breast or lymph node) after chemotherapy and surgery. View full eligibility criteria

Purpose: To collect blood and tissue samples from people with breast cancer and people without breast cancer to evaluate tests for early cancer detection.

Who is this for?: People 40-75 years old with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have not yet received treatment, or who do not have breast cancer. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of camizestrant, an experimental hormone therapy, compared to standard of care hormone therapy.

Who is this for?: People with stage I, stage II, or some stage III estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have received surgery less than 1 year ago and have completed standard treatment. You must not have received fulvestrant (Faslodex®). View full eligibility criteria

Purpose: To analyze blood samples from women at high risk of developing breast cancer in order to learn more about how cells change over time from normal to cancerous.

Who is this for?: Women at high-risk for developing breast cancer. View full eligibility criteria

Purpose: To study the safety, anti-cancer activity and side effects of giving an experimental immunotherapy made from cells from your own immune system.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer. View full eligibility criteria

Purpose: To determine if immediate lymphatic reconstruction during lymph node removal reduces the risk of developing lymphedema and improves quality of life.

Who is this for?: Women with stage I, stage II, or stage III breast cancer who are planning to receive lymph node removal. You must not have received radiation to the lymph node that will be removed. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of XMT-2056, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer or breast cancer with a HER2 mutation who have received standard treatment. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of disitamab vedotin antibody-drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+), HER2 low, or HER2 ultralow breast cancer. You must have received 1-3 prior lines of therapy for advanced disease. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of LY4257496 GRPR radiopharmaceutical with or without standard of care therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+) breast cancer. Your tumor must be positive for gastrin-releasing peptide receptor (GRPR). View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of LY4337713 radiopharmaceutical.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that is positive for fibroblast activation protein (FAP) who have received at least 1 line of therapy. View full eligibility criteria

Purpose: To look at the effect radiation therapy has on DCIS cancer cells and surrounding tissue when it is given before surgery.

Who is this for?: Women with ductal carcinoma in situ (DCIS) who has not yet started cancer treatment. View full eligibility criteria

Purpose: To evaluate the safety and effects (good and bad) of eFT226 (Zotatifin), an experimental targeted therapy that blocks eIF4A1.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that has been treated with standard therapies and tests positive for a mutation in HER2 (ERRB2), ERBB3, FGFR1, FGFR2, or KRAS. View full eligibility criteria

Purpose: To use circulating tumor DNA (ctDNA) to identify who will or will not experience benefit from adjuvant (after surgery) capecitabine (Xeloda®) chemotherapy.

Who is this for?: People with stage I, stage II, or stage III triple negative (ER- or ER low, PR- or PR low, HER2-) breast cancer who have residual disease after neoadjuvant (before surgery) chemotherapy and surgery. You must be planning to receive capecitabine (Xeloda®) after surgery. View full eligibility criteria

Purpose: To study if tumors have HLA gene changes and to store immune cells that will be used to create a future immunotherapy treatment.

Who is this for?: People with some stage III (advanced) or stage IV (metastatic) triple negative (ER-, PR-, HER2-) breast cancer. View full eligibility criteria

Purpose: To compare the safety and effects (good and bad) of Interi Drains to standard of care Jackson-Pratt (JP) Drains during bilateral (both breast) mastectomy.

Who is this for?: Women 18-65 years old with stage I, stage II, or stage III breast cancer who are planning to receive a bilateral (both breasts) mastectomy with immediate reconstruction. View full eligibility criteria

Purpose: To study the use of a ctDNA blood test to predict recurrence.

Who is this for?: People with stage I, stage II, or stage III breast cancer who are planning to receive neoadjuvant (before surgery) chemotherapy. View full eligibility criteria

Purpose: To study the safety, best dose, and effects (good and bad) of [177Lu]Lu-NNS309, an experimental radioactive drug.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) or triple negative (ER-, PR-, HER2-) breast cancer who have received at least 2 lines of therapy for advanced disease. View full eligibility criteria

Purpose: To study how multi-cancer detection (MCD) tests may work as cancer screening tools.

Who is this for?: People, aged 45-75 years, without cancer. People with stage 0 (DCIS) breast cancer may enroll. View full eligibility criteria

Purpose: To study if ribociclib (Kisqali®) CDK4/6 inhibitor with hormone therapy increases the amount of time before breast cancer comes back.

Who is this for?: People with some stage II or stage III hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer whose surgical margins do not have cancer. You must have begun hormone therapy in the last 3 years and be planning to receive hormone therapy for at least 3 more years. View full eligibility criteria

Purpose: To determine the safety, side effects, dose, and anti-cancer activity of AZD8205, and antibody-drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer. You must not have received more than one line of therapy. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of PRO1184, an experimental antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer that expresses folate receptor alpha (FRA) who have received standard treatment. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of lasofoxifene, an experimental hormone therapy, with abemaciclib (Verzenio®) CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer with an ESR1 mutation. You must have received an aromatase inhibitor with palbociclib (Ibrance®) or ribociclib (Kisqali®) CDK4/6 inhibitor as your first line of hormone therapy for advanced disease. You must not have received more than 1 line of chemotherapy for advanced disease. View full eligibility criteria

Purpose: To study the safety and effects (good and bad) of RE104 for Injection to reduce depression and/or anxiety.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer with adjustment disorder that includes depression and/or anxiety that has lasted for at least 1 month. View full eligibility criteria

Purpose: To study the ability of the BostonGene Tumor Portrait test to provide information about tumors and their microenvironment and help make treatment decisions.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria